Fuyu Tamanoi, Ph.D.
Richard Finn, M.D.
The Signal Transduction and Therapeutics Program investigates the multiple signaling pathways and related genetic alterations that occur during formation of cancer cells and tumors. Signal transduction pathway studies are carried out by employing phospho-protein analysis, cell cycle, gene expression studies and chemical genetics approaches.
For more information, please visit the program's website at: http://www.sttprogram.ucla.edu/
- To understand signal transduction events in the development of cancer by identifying new genes involved in cell signaling pathways
- To develop new methods to detect changes in signaling events
- To develop inhibitors of signal transduction that could lead to new anti-cancer therapies
Meetings and Events:
- Quarterly meetings for new members to present their research
- Quarterly seminars given by members of the program area
- Quarterly seminars given by invited speakers from outside institutions
- Twice a year mini-symposia on Signal Transduction and Cancer Therapeutics
Dr. Fuyu Tamanoi, Director of the Signal Transduction and Therapeutics Program Area, has been engaged in the study of the Ras protein for the past twenty years. This protein plays a central role in the growth factor signaling pathway, and has been studied as a model system for the function of small G-proteins. Tamanoi's laboratory studies the mechanisms of Ras membrane association. Tamanoi has also been instrumental in identifying and characterizing inhibitors of farnesyltransferase which are being evaluated in clinical trials. In addition, his lab is involved in the characterization of the TSC/Rheb/mTOR signaling pathway that is critical for growth in response to nutrient and energy conditions.